Neogen Corporation — Form 10-K Summary
Reporting period: Fiscal year ended May 31, 2012, with comparisons to fiscal 2011 and 2010. The filing also reports fourth-quarter results for the quarter ended May 31, 2012. Although the request metadata says “2011 Q4,” the filing covers fiscal 2012.
Business context
Neogen develops, manufactures and markets food-safety testing products and animal-safety products and services, including veterinary products, rodenticides, disinfectants and animal genomics. Fiscal 2012 revenue was nearly evenly divided between Food Safety (49.5%) and Animal Safety (50.5%); international sales were 41.7% of total revenue.
Key financial results
| Metric | FY2012 | FY2011 |
|---|---|---|
| Net sales | $184.046 million | $172.683 million |
| Gross margin | $92.425 million; 50.2% | $87.792 million; 50.8% |
| Operating income | $33.739 million; 18.3% of sales | $35.835 million; 20.7% of sales |
| Net income | $22.513 million | $22.839 million |
| Diluted EPS | $0.94 | $0.96 |
| Cash from operations | $22.277 million | $28.843 million |
| Cash and marketable securities at year-end | $68.645 million | $56.083 million |
| Working capital at year-end | $123.962 million | $104.705 million |
| Long-term debt | $0 | $0 |
Year-end total assets were $251.600 million and total equity was $219.054 million. The company had an unused $12 million revolving credit facility. Capital expenditures and other non-current asset purchases used $12.413 million of cash. Fourth-quarter FY2012 sales were $48.546 million, net income was $6.028 million, and diluted EPS was $0.25; the prior-year fourth quarter recorded sales of $43.594 million, net income of $5.962 million and diluted EPS of $0.25.
Changes versus prior year
- Sales grew 7%, while net income fell 1% and diluted EPS declined from $0.96 to $0.94.
- Gross margin declined 0.6 percentage points, mainly due to Animal Safety product mix. Operating expenses rose 13%, with sales and marketing expense up 17%, reflecting investment in personnel and infrastructure; operating income consequently fell 6%.
- Food Safety sales increased 7% to $91.104 million; Animal Safety sales increased 7% to $92.942 million. Rodenticides and disinfectants declined 6%, while veterinary instruments and other products grew 21%.
- Operating cash flow decreased by $6.566 million, partly reflecting higher receivables and inventory. Receivables rose 25% and days sales outstanding increased from 57 to 60 days.
- The May 2012 Igenity asset acquisition added genomics capabilities but contributed little revenue in FY2012. The June 2011 VeroMara acquisition added seafood-testing services.
Outlook, risks and unusual items
- Management did not provide forecasts of future financial performance. It described long-term prospects optimistically and identified growth priorities including new products, broader customer use, international expansion and acquisitions. New product launches were expected during fiscal 2013–2015; planned R&D spending was approximately 3%–5% of revenue.
- Management said sales and marketing and infrastructure investments were intended to support greater market penetration and future operating performance. It also noted current funds might not be sufficient for product commercialization and additional acquisitions, and that the company could issue equity or seek other financing.
- Key risks include acquisition integration and growth management, competition and technology changes, agricultural and commodity-market cycles and weather, international regulation and currency movements, supply or manufacturing disruption, product-development failure, intellectual-property disputes, government regulation, product liability and dependence on key employees. The company reported no material legal proceedings; routine proceedings were not expected by management to materially affect results or financial position.
- FY2012 results included a $550,000 reversal of uncertain tax-position reserves following conclusion of an IRS audit, reducing the reported effective tax rate to 33.7% (35.3% absent the adjustment). Foreign-currency transaction losses were $531,000. Prior-year other expense included a $787,000 increase in the GeneSeek contingent payment obligation; FY2012 included a $154,000 reversal of that obligation.
- Environmental remediation at the Randolph, Wisconsin facility carried an estimated $916,000 liability, with annual remediation costs historically ranging from $50,000 to $105,000. The filing reports no cash dividends paid and none anticipated in the foreseeable future.
Important facts for investors to verify
- Whether sales growth can translate into improved margins and operating income after the recent expense and personnel investments.
- Collection performance and credit exposure: receivables increased, DSO rose to 60 days, and one customer represented about 10% of year-end receivables.
- Integration and future contribution of Igenity, and the performance of GeneSeek and other acquired businesses.
- Cash needs for acquisitions, product commercialization and facility expansion, including the planned approximately $1.5 million purchase of an adjacent Scotland facility.
- Exposure to foreign exchange, regulatory changes, supply constraints, agricultural conditions and the $916,000 environmental remediation estimate.